

## Highlights of This Issue 1085

## REVIEW

- 1087** Targeting Wnts at the Source—New Mechanisms, New Biomarkers, New Drugs  
Babita Madan and David M. Virshup

## SMALL MOLECULE THERAPEUTICS

- 1095** P7170: A Novel Molecule with Unique Profile of mTORC1/C2 and Activin Receptor-like Kinase 1 Inhibition Leading to Antitumor and Antiangiogenic Activity  
Archana Jalota-Badhwar, Dimple R. Bhatia, Srinivas Boreddy, Asavari Joshi, Magesh Venkatraman, Nikesh Desai, Sarika Chaudhari, Julie Bose, Lakshmi S. Kolla, Vijaykumar Deore, Nilambari Yewalkar, Sanjay Kumar, Rajiv Sharma, Anagha Damre, Avinash More, Somesh Sharma, and Veena R. Agarwal
- 1107** Hsp27 Inhibition with OGX-427 Sensitizes Non-Small Cell Lung Cancer Cells to Erlotinib and Chemotherapy  
Barbara Lelj-Garolla, Masafumi Kumano, Eliana Beraldi, Lucia Nappi, Palma Rocchi, Diana N. Ionescu, Ladan Fazli, Amina Zoubeidi, and Martin E. Gleave
- 1117** p53 Family Members Regulate Phenotypic Response to Aurora Kinase A Inhibition in Triple-Negative Breast Cancer  
John J. Tentler, Anastasia A. Ionkina, Aik Choon Tan, Timothy P. Newton, Todd M. Pitts, Magdalena J. Glogowska, Peter Kabos, Carol A. Sartorius, Kelly D. Sullivan, Joaquin M. Espinosa, S. Gail Eckhardt, and Jennifer R. Diamond

## LARGE MOLECULE THERAPEUTICS

- 1130** High Turnover of Tissue Factor Enables Efficient Intracellular Delivery of Antibody-Drug Conjugates  
 Bart E.C.G. de Goeij, David Satijn, Claudia M. Freitag, Richard Wubbolts, Wim K. Bleeker, Alisher Khasanov, Tong Zhu, Gary Chen, David Miao, Patrick H.C. van Berkel, and Paul W.H.I. Parren

- 1141** Characterization of ABT-806, a Humanized Tumor-Specific Anti-EGFR Monoclonal Antibody  
Edward B. Reilly, Andrew C. Phillips, Fritz G. Buchanan, Gillian Kingsbury, Yumin Zhang, Jonathan A. Meulbroek, Todd B. Cole, Peter J. DeVries, Hugh D. Falls, Christine Beam, Jimming Gu, Enrico L. Digiammarino, Joann P. Palma, Cherrie K. Donawho, Neal C. Goodwin, and Andrew M. Scott

## CANCER BIOLOGY AND SIGNAL TRANSDUCTION

- 1152**  $\beta$ III-Tubulin Regulates Breast Cancer Metastases to the Brain  
Deepak Kanojia, Ramin A. Morshed, Lingjiao Zhang, Jason M. Miska, Jian Qiao, Julius W. Kim, Peter Pytel, Irina V. Balyasnikova, Maciej S. Lesniak, and Atique U. Ahmed
- 1162** HOTAIR Long Noncoding RNA Promotes Gastric Cancer Metastasis through Suppression of Poly r(C)-Binding Protein (PCBP) 1  
Zi-Zhen Zhang, Zhi-Yong Shen, Yan-Ying Shen, En-Hao Zhao, Ming Wang, Chao-Jie Wang, Hui Cao, and Jia Xu
- 1171** Radiosensitization of Primary Human Glioblastoma Stem-like Cells with Low-Dose AKT Inhibition  
Monal Mehta, Atif Khan, Shabbar Danish, Bruce G. Haffty, and Hatem E. Sabaawy
- 1181** The Tyrosine Kinase Inhibitors Imatinib and Dasatinib Reduce Myeloid Suppressor Cells and Release Effector Lymphocyte Responses  
Lisa Christiansson, Stina Söderlund, Sara Mangsbo, Henrik Hjorth-Hansen, Martin Höglund, Berit Markevörn, Johan Richter, Leif Stenke, Satu Mustjoki, Angelica Loskog, and Ulla Olsson-Strömberg
- 1192** Endostatin Has ATPase Activity, Which Mediates Its Antiangiogenic and Antitumor Activities  
Shan Wang, Xin-an Lu, Peng Liu, Yan Fu, Lin Jia, Shunli Zhan, and Yongzhang Luo
- 1202** Frequent Loss of NISCH Promotes Tumor Proliferation and Invasion in Ovarian Cancer via Inhibiting the FAK Signal Pathway  
Jing Li, Xiaoying He, Ruofan Dong, Yuan Wang, Jinjin Yu, and Haifeng Qiu

# Table of Contents

- 1213** Synthetic Lethal Screens Identify Vulnerabilities in GPCR Signaling and Cytoskeletal Organization in E-Cadherin–Deficient Cells  
Bryony J. Telford, Augustine Chen, Henry Beetham, James Frick, Tom P. Brew, Cathryn M. Gould, Andrew Single, Tanis Godwin, Kaylene J. Simpson, and Parry Guilford

## COMPANION DIAGNOSTICS AND CANCER BIOMARKERS

- 1224** Loss of Tuberous Sclerosis Complex 2 (TSC2) Is Frequent in Hepatocellular Carcinoma and Predicts Response to mTORC1 Inhibitor Everolimus  
Hung Huynh, Huai-Xiang Hao, Stephen L. Chan, David Chen, Richard Ong, Khee Chee Soo, Panisa Pochanard, David Yang, David Ruddy, Manway Liu, Adnan Derti, Marissa N. Balak, Michael R. Palmer, Yan Wang, Benjamin H. Lee, Dalila Sellami, Andrew X. Zhu, Robert Schlegel, and Alan Huang
- 1236** MGMT Expression Predicts PARP-Mediated Resistance to Temozolomide  
Oihane Erice, Michael P. Smith, Rachel White, Ibai Goicoechea, Jorge Barriuso, Chris Jones, Geoffrey P. Margison, Juan C. Acosta, Claudia Wellbrock, and Imanol Arozarena

## MODELS AND TECHNOLOGIES

- 1247** Enhancement of the Proapoptotic Properties of Newcastle Disease Virus Promotes Tumor Remission in Syngeneic Murine Cancer Models  
Sara Cuadrado-Castano, Juan Ayllon, Mena Mansour, Janis de la Iglesia-Vicente, Stefan Jordan, Shashank Tripathi, Adolfo García-Sastre, and Enrique Villar
- 1259** RNA Interference Using *c-Myc*–Conjugated Nanoparticles Suppresses Breast and Colorectal Cancer Models  
Naveen K. Tangudu, Vinod K. Verma, Tristan D. Clemons, Syed S. Beevi, Trevor Hay, Ganesh Mahidhara, Meera Raja, Rekha A. Nair, Liza E. Alexander, Anant B. Patel, Jedy Jose, Nicole M. Smith, Bogdan Zdyrko, Anne Bourdoncle, Igor Luzinov, K. Swaminathan Iyer, Alan R. Clarke, and Lekha Dinesh Kumar




AC icon indicates Author Choice

For more information please visit [www.aacrjournals.org](http://www.aacrjournals.org)

## ABOUT THE COVER

The newly generated Newcastle disease virus rNDV-B1/Fas encodes the human TNF receptor Fas. Human and murine cancer cells infected by rNDV-B1/Fas displayed a modified cell death response compared with the wild-type rNDV-B1, characterized by an earlier and enhanced apoptosis response due to the overexpression of Fas following the coactivation of both extrinsic and intrinsic apoptosis pathways. The enhanced cytotoxicity shown *in vitro* correlated with an improved oncolytic activity and therapeutic effect of rNDV-B1/Fas virus in intratumoral-treated melanoma-bearing mice. The cover image shows murine B16-F10 melanoma cells infected by rNDV-B1/Fas virus. The human Fas receptor (red) is expressed on the surface of infected cells (green) but also internalized following induction of apoptosis. DNA was counterstained with Hoechst. For details, see the article by Cuadrado-Castano and colleagues on page 1247.



# Molecular Cancer Therapeutics

**14 (5)**

*Mol Cancer Ther* 2015;14:1085-1269.

**Updated version** Access the most recent version of this article at:  
<http://mct.aacrjournals.org/content/14/5>

**E-mail alerts** [Sign up to receive free email-alerts](#) related to this article or journal.

**Reprints and Subscriptions** To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at [pubs@aacr.org](mailto:pubs@aacr.org).

**Permissions** To request permission to re-use all or part of this article, use this link <http://mct.aacrjournals.org/content/14/5>. Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.